Mehta Analysis: How Buffett And Friends Can Succeed, And How Pharma Would Be Affected
How Warren Buffett's company Berkshire Hathaway, Amazon and JPMorgan will address the challenge of creating affordable, quality healthcare for their employees in the US is far from clear, but they are intent on trying. Viren Mehta, founding partner of Mehta Partners LLC, considers what approach they might take to succeed where others have failed, and how such a course would impact on the pharma sector.
You may also be interested in...
Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.
Change, which could have multi-billion dollar impact on some large companies over 10 years, is framed as way to lower premiums in Medicare Part D.
Health Transformation Alliance is more interested in how a drug might reduce other medical costs than in pricing alone, CEO Andrews says.